10.86
0.08 (0.70%)
| Penutupan Terdahulu | 10.78 |
| Buka | 10.79 |
| Jumlah Dagangan | 749,050 |
| Purata Dagangan (3B) | 1,616,461 |
| Modal Pasaran | 1,274,647,936 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.24 |
| Harga / Jualan (P/S) | 5.84 |
| Harga / Buku (P/B) | 3.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -20.39% |
| Margin Operasi (TTM) | -31.40% |
| EPS Cair (TTM) | -0.500 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 34.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 3,119.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 54.64% |
| Nisbah Semasa (MRQ) | 11.93 |
| Aliran Tunai Operasi (OCF TTM) | 63.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 33.54 M |
| Pulangan Atas Aset (ROA TTM) | -0.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -10.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Menaik | |
| Stok | Dynavax Technologies Corporatio | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.83 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.58% |
| % Dimiliki oleh Institusi | 108.60% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Dec 2025 | Pengumuman | Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline |
| 19 Nov 2025 | Pengumuman | Dynavax to Participate at the 8th Annual Evercore Healthcare Conference |
| 05 Nov 2025 | Pengumuman | Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program |
| 05 Nov 2025 | Pengumuman | Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |